» Articles » PMID: 27134713

Langerhan's Cell Sarcoma: Two Case Reports

Overview
Journal Rare Tumors
Publisher Sage Publications
Specialty Oncology
Date 2016 May 3
PMID 27134713
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Langerhan's cell sarcoma (LCS) is a rare neoplasm with a poor prognosis. To our knowledge, only sixty-six cases have been published. We discuss two patients who presented very differently with LCS, as well as a recently published review of all sixty-six cases. Our first case had a complicated history of metastatic, high-grade myxofibrosarcomas and presented with a single skin lesion of LCS which was treated with resection to a positive margin and adjuvant radiotherapy. The LCS recurred locoregionally and was again resected. The patient is alive two years after initial diagnosis. The second case presented with bone marrow and splenic involvement, leukocytosis, and thrombocytopenia. This patient had an excellent response to etoposide, prednisone, oncovorin, cyclophosphamide, and adriamycin, with normalization of the complete blood count, negative bone marrow biopsy at follow up, and splenectomy without viable neoplasm. This patient is alive without signs of disease at 16 months after initial diagnosis.

Citing Articles

Complexity of diagnosing and treating langerhans cell sarcoma: A case report.

Charfi M, Lajnaf M, Kallel F, Saguem I, Kassar O, Elloumi M Tunis Med. 2024; 101(7):651-653.

PMID: 38445429 PMC: 11217968.


Langerhans Cell Histiocytosis of the Temporal Bone.

Mayer S, Raggio B, Master A, Lygizos N Ochsner J. 2020; 20(3):315-318.

PMID: 33071667 PMC: 7529136. DOI: 10.31486/toj.19.0032.


Successful treatment of an elderly Langerhans cell sarcoma patient by EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) chemotherapy.

Matsukawa T, Suto K, Miyoshi H, Oshimi K, Ohshima K, Miyagishima T J Clin Exp Hematop. 2018; 58(4):184-187.

PMID: 30305476 PMC: 6407472. DOI: 10.3960/jslrt.18027.

References
1.
Nakayama M, Takahashi K, Hori M, Okumura T, Saito M, Yamakawa M . Langerhans cell sarcoma of the cervical lymph node: a case report and literature review. Auris Nasus Larynx. 2010; 37(6):750-3. DOI: 10.1016/j.anl.2010.04.007. View

2.
Sagransky M, Deng A, Magro C . Primary cutaneous langerhans cell sarcoma: a report of four cases and review of the literature. Am J Dermatopathol. 2012; 35(2):196-204. DOI: 10.1097/DAD.0b013e3182661c0b. View

3.
Pileri S, Grogan T, Harris N, Banks P, Campo E, Chan J . Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases. Histopathology. 2002; 41(1):1-29. DOI: 10.1046/j.1365-2559.2002.01418.x. View

4.
Valladeau J, Ravel O, Dezutter-Dambuyant C, Moore K, Kleijmeer M, Liu Y . Langerin, a novel C-type lectin specific to Langerhans cells, is an endocytic receptor that induces the formation of Birbeck granules. Immunity. 2000; 12(1):71-81. DOI: 10.1016/s1074-7613(00)80160-0. View

5.
Kwong Y . Cutaneous Langerhans cell sarcoma relapsing systemically: Complete remission with the EPIG regimen. Ann Hematol. 2014; 94(4):697-9. DOI: 10.1007/s00277-014-2203-0. View